Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 47, Issue 7, Pages 896-905
Publisher
Wiley
Online
2018-02-12
DOI
10.1111/apt.14550
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium
- (2017) Parambir Dulai et al. GASTROENTEROLOGY
- Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease
- (2017) Christopher Ma et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
- (2017) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
- (2017) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease
- (2017) Maria Rosario et al. Journal of Crohns & Colitis
- Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
- (2017) Franco Scaldaferri et al. PLoS One
- Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
- (2017) Carl Eriksson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents
- (2016) Pauline Wils et al. Clinical Gastroenterology and Hepatology
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
- (2016) Aurelien Amiot et al. Clinical Gastroenterology and Hepatology
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab
- (2016) Kimberly A. Harris et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab for the Treatment of Refractory Crohnʼs Disease
- (2016) Sam Khorrami et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
- (2015) M. Rosario et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- Factors Associated with Durable Response to Infliximab in Crohnʼs Disease 5 Years and Beyond
- (2015) Pascal Juillerat et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
- (2014) Niels Vande Casteele et al. GUT
- Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
- (2014) U. Kopylov et al. Journal of Crohns & Colitis
- Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
- (2013) Gordon W. Moran et al. Clinical Gastroenterology and Hepatology
- Adalimumab in active ulcerative colitis: A “real-life” observational study
- (2013) Alessandro Armuzzi et al. DIGESTIVE AND LIVER DISEASE
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease
- (2013) Clas-Göran af Björkesten et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
- (2010) Stefan Schreiber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now